Blacksmith Medicines Advances Novel Antibiotic Discovery
San Diego, California, USA, August 8, 2026 Blacksmith Medicines has announced the publication of new research in the Journal...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
San Diego, California, USA, August 8, 2026 Blacksmith Medicines has announced the publication of new research in the Journal...
CAMBRIDGE, United Kingdom, July 6, 2026 Astex Pharmaceuticals has entered into an exclusive worldwide research collaboration and license agreement...
BASEL, Switzerland, June 12, 2026 Novartis announced new Phase III data at the European Academy of Allergy and Clinical...
BOSTON and SHENZHEN, China, June 10, 2026 XtalPi, a global leader in AI and robotics-driven drug discovery, has announced...
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...
TOKYO, Japan & CAMBRIDGE, Mass., March 13, 2026 PRISM BioLab Co., Ltd. and Receptor.AI Inc. have announced a strategic...
HONG KONG, Jan. 5, 2026 — Ascletis Pharma Inc. announced that it has received Investigational New Drug (IND) clearance...
SAN MATEO, Calif., October 8, 2025 — Vivace Therapeutics, Inc., a biotechnology company pioneering small molecule cancer therapies that...
